Status:
RECRUITING
Eficacia Ventilatoria y Remolacha
Lead Sponsor:
Hospital de Mataró
Conditions:
SARS CoV 2 Infection
Muscle Disorder
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The lung is the organ most affected by COVID-19. There are patients who successfully overcome the acute COVID-19 infection and their lungs return to a normal state. However, a significant number prese...
Detailed Description
Long COVID is a multisystem condition that comprises a set of symptoms following a SARS-CoV-2 infection. At least 65 million people around the world present symptoms associated with persistent COVID, ...
Eligibility Criteria
Inclusion
- Patients with fatigue after SARS CoV2 infection.
- Written informed consent signed by the study candidates (see Addendum 1), after receiving complete information about the objectives, techniques and possible consequences of the study.
Exclusion
- Previous cardiovascular, oncological, neuromuscular or metabolic pathologies that could interfere with the results.
- Significant alcoholism (\>80 g/day) or severe malnutrition
- Chronic treatment with drugs with potential effects on muscle structure and function
- Patient treated with nitrates
- Patients diagnosed prior to the infection with fibromyalgia or chronic fatigue.
- Patient who has a contraindication to carrying out a stress test.
- Patients allergic to beets
Key Trial Info
Start Date :
November 13 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06217211
Start Date
November 13 2023
End Date
May 31 2024
Last Update
January 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eulogio Pleguezuelos
Mataró, Barcelona, Spain, 08304